CHICAGO, IL—An investigational agent given by subcutaneous injection can drastically reduce levels of lipoprotein (a), with ...

Eli Lilly (NYSE:LLY) released positive Phase 2 results for its small interfering RNA (siRNA) drug candidate lepodisiran on Sunday. The trial results showed 94% lower levels of a genetically inherited ...

CHICAGO -- Novel small interfering RNA (siRNA) agent lepodisiran drastically ... associated with increased intracranial hemorrhage and diabetes in observational studies, Gianos noted.

Reporting in Nature, Kumar and colleagues have now developed a method to target small-interfering RNA (siRNA) to the CNS, providing a safe and non-invasive approach for the delivery of this new ...